Search results | NICE

2 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Last 6 months Remove Last 6 months filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies

Type

Highly specialised technologies guidance

Published

07 July 2021
View recommendations for HST15

Show all sections for HST15
Sections for HST15

Overview

1 Recommendations

2 The condition

3 The technology

4 Consideration of the evidence

5 Implementation

6 Evaluation committee members and NICE project team
Metreleptin for treating lipodystrophy (HST14)

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021
View recommendations for HST14

Show all sections for HST14
Sections for HST14

Overview

1 Recommendations

2 The condition

3 The technology

4 Consideration of the evidence

5 Implementation

6 Evaluation committee members and NICE project team

Update information